Chemically modified recombinant human sulfamidase (SOBI003) in mucopolysaccharidosis IIIA patients: Results from an open, non-controlled, multicenter study
Under a Creative Commons license
open access
Keywords
Mucopolysaccharidosis IIIA
Chemically modified recombinant human sulfamidase
Heparan sulfate
Plasma exposure
Blood–brain barrier
Anti-drug antibodies
Cited by (0)
- 1
Affibody AB, Solna, Sweden.
- 2
Oncopeptides AB, Stockholm, Sweden.
- 3
Mölnlycke Health Care AB, Gothenburg, Sweden.
- 4
Oncopeptides AB, Solna, Sweden.
- 5
Biologics Immunology & Analytics - BIA AB, Stockholm, Sweden.
- 6
AlzeCure Pharma AB, Huddinge, Sweden.
- 7
InDex Pharmaceuticals, Solna, Sweden.
© 2022 The Authors. Published by Elsevier Inc.